{"id":"W3087210493","doi":"10.1056/nejmoa2027071","title":"Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1756,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Chugai Pharmaceutical; EMD Serono; Genentech; Ono Pharmaceutical; Shionogi; Loxo Oncology; Astellas Pharma; Mirati Therapeutics; Daiichi Sankyo Europe; Sanofi; Halozyme; F. Hoffmann-La Roche; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Spectrum Pharmaceuticals; Amgen; Kyorin Pharmaceutical; Pfizer; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Osimertinib; Lung cancer; Medicine; Cancer research; Oncology; Internal medicine; Cancer; Epidermal growth factor receptor; Erlotinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02115782651282301,"score_gpt":0.3285523371855753,"score_spread":0.3073945106727523,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}